Stock Track | Novavax Soars 5.06% Despite Price Target Cut as B. Riley Maintains Buy Rating

Stock Track

16 hours ago

Novavax (NVAX) shares are soaring 5.06% in Tuesday's intraday trading session, defying a price target reduction from B. Riley. The biopharmaceutical company's stock is showing resilience in the face of adjusted analyst expectations, suggesting investors remain optimistic about its prospects.

B. Riley, a prominent financial services firm, has lowered its price target for Novavax from $18 to $16. However, the firm has maintained its Buy rating on the stock, indicating continued confidence in Novavax's potential. This new target price, while reduced, still represents significant upside potential from current trading levels, which may be fueling investor enthusiasm.

The market's positive reaction, despite the lowered price target, could be attributed to several factors. Investors might be focusing on the maintained Buy rating, which suggests that B. Riley still sees strong growth potential for Novavax. Additionally, the average rating for Novavax among analysts polled by FactSet remains "overweight," with a mean price target of $13.62. This broader consensus, combined with B. Riley's higher target, may be reinforcing bullish sentiment among traders and driving the stock's impressive intraday gains.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1197959101"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1197959101\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1197959101?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 02:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197959101","market":"sg","top_or_hot":-1,"title":"Stock Track | Novavax Soars 5.06% Despite Price Target Cut as B. Riley Maintains Buy Rating","media":"Stock Track","content":"<p>Novavax (NVAX) shares are soaring 5.06% in Tuesday's intraday trading session, defying a price target reduction from B. Riley. The biopharmaceutical company's stock is showing resilience in the face of adjusted analyst expectations, suggesting investors remain optimistic about its prospects.</p>\n\n<p>B. Riley, a prominent financial services firm, has lowered its price target for Novavax from $18 to $16. However, the firm has maintained its Buy rating on the stock, indicating continued confidence in Novavax's potential. This new target price, while reduced, still represents significant upside potential from current trading levels, which may be fueling investor enthusiasm.</p>\n\n<p>The market's positive reaction, despite the lowered price target, could be attributed to several factors. Investors might be focusing on the maintained Buy rating, which suggests that B. Riley still sees strong growth potential for Novavax. Additionally, the average rating for Novavax among analysts polled by FactSet remains \"overweight,\" with a mean price target of $13.62. This broader consensus, combined with B. Riley's higher target, may be reinforcing bullish sentiment among traders and driving the stock's impressive intraday gains.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novavax Soars 5.06% Despite Price Target Cut as B. Riley Maintains Buy Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novavax Soars 5.06% Despite Price Target Cut as B. Riley Maintains Buy Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-12 02:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novavax (NVAX) shares are soaring 5.06% in Tuesday's intraday trading session, defying a price target reduction from B. Riley. The biopharmaceutical company's stock is showing resilience in the face of adjusted analyst expectations, suggesting investors remain optimistic about its prospects.</p>\n\n<p>B. Riley, a prominent financial services firm, has lowered its price target for Novavax from $18 to $16. However, the firm has maintained its Buy rating on the stock, indicating continued confidence in Novavax's potential. This new target price, while reduced, still represents significant upside potential from current trading levels, which may be fueling investor enthusiasm.</p>\n\n<p>The market's positive reaction, despite the lowered price target, could be attributed to several factors. Investors might be focusing on the maintained Buy rating, which suggests that B. Riley still sees strong growth potential for Novavax. Additionally, the average rating for Novavax among analysts polled by FactSet remains \"overweight,\" with a mean price target of $13.62. This broader consensus, combined with B. Riley's higher target, may be reinforcing bullish sentiment among traders and driving the stock's impressive intraday gains.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"","article_id":"1197959101","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197959101","pubTimestamp":1762887270,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Novavax (NVAX) shares are soaring 5.06% in Tuesday's intraday trading session, defying a price target reduction from B. Riley. The biopharmaceutical company's stock is showing resilience in the face...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"股票追踪|尽管目标价下调，Novavax仍飙升5.06%，B.Riley维持买入评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":1},"content_text":"Novavax (NVAX) shares are soaring 5.06% in Tuesday's intraday trading session, defying a price target reduction from B. Riley. The biopharmaceutical company's stock is showing resilience in the face of adjusted analyst expectations, suggesting investors remain optimistic about its prospects.\nB. Riley, a prominent financial services firm, has lowered its price target for Novavax from $18 to $16. However, the firm has maintained its Buy rating on the stock, indicating continued confidence in Novavax's potential. This new target price, while reduced, still represents significant upside potential from current trading levels, which may be fueling investor enthusiasm.\nThe market's positive reaction, despite the lowered price target, could be attributed to several factors. Investors might be focusing on the maintained Buy rating, which suggests that B. Riley still sees strong growth potential for Novavax. Additionally, the average rating for Novavax among analysts polled by FactSet remains \"overweight,\" with a mean price target of $13.62. This broader consensus, combined with B. Riley's higher target, may be reinforcing bullish sentiment among traders and driving the stock's impressive intraday gains.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}